In NASH, liraglutide can induce PINK1-Parkin-mediated mitosis, thereby limiting ROS production and inhibiting NLRP3-mediated hepatocyte pyroptosis (Yu et al., 2019). Here, PINK1 is linked to metabolic dysfunction-associated steatohepatitis.